SCHEMBL4268670

SCHEMBL4268670

C=CCOC(=O)C(CC=C)(Cc1cccc(C(F)(F)F)c1)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.45
MAPK1 P28482 1/20 0.45
RAB9A P51151 1/20 0.45
NR4A2 P43354 2/20 0.40
PRKCA P17252 1/20 0.40
PRKCD Q05655 1/20 0.40
TGM2 P21980 1/20 0.40
ALDH1A1 P00352 2/20 0.39
HTT P42858 2/20 0.39
MAPT P10636 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ACP3 P15309 1/20 0.39
MMP1 P03956 1/20 0.38
MMP12 P39900 1/20 0.38
FFAR1 O14842 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
PTPN1 P18031 1/20 0.38
TSHR P16473 1/20 0.38
PPARG P37231 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4262187 0.79 MAPT (0.43) LMNAMAPK1RAB9ANR4A2PRKCA
SCHEMBL13912551 0.75 MAPT (0.40) LMNAMAPK1RAB9ANR4A2PRKCA
SCHEMBL29100373 0.74 CYP3A4 (0.50) MAPK1ALDH1A1MEN1KMT2APTPN1
SCHEMBL3092243 0.73 EPHX1 (0.50) LMNANR4A2ALDH1A1MAPTMEN1
SCHEMBL4261485 0.73 LMNA (0.50) LMNAMAPK1RAB9ANR4A2PRKCA
SCHEMBL10556756 0.72 CYP3A4 (0.36) ALDH1A1HTTMAPTMEN1KMT2A
SCHEMBL14780442 0.71 CES2 (0.56) LMNAMAPK1RAB9APRKCAPRKCD
SCHEMBL29010009 0.70 ACP3 (0.54) NR4A2PRKCAPRKCDMAPTMEN1
SCHEMBL16892926 0.69 EPHX1 (0.56) MAPTMEN1KMT2AACP3MAOB
SCHEMBL11775522 0.68 CYP3A4 (0.46) MAPK1ALDH1A1HTTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060094747-A1 Substituted carboxylic acids THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, L.L.C. 2006-05-04 US claimed
US-20090082392-A1 Substituted Carboxylic Acids THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC 2009-03-26 US disclosed
US-7358364-B2 treatment of diabetes and/or cancer; useful in the treatment of syndrome X; capable of inhibiting Protein tyrosine phosphatase THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC (US) 2008-04-15 US disclosed
EP-1805159-A1 SUBSTITUTED CARBOXYLIC ACIDS The Institutes for Pharmaceutical Discovery, LLC (US) 2007-07-11 EP disclosed
WO-2006050212-A1 SUBSTITUTED CARBOXYLIC ACIDS THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC (US) 2006-05-11 WO disclosed
US-20060094747-A1 Substituted carboxylic acids THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY, L.L.C. 2006-05-04 US disclosed
EP-1620420-A2 SUBSTITUTED CARBOXYLIC ACIDS The Institutes for Pharmaceutical Discovery, LLC (US) 2006-02-01 EP disclosed
US-20040266788-A1 Substituted carboxylic acids THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC 2004-12-30 US disclosed
WO-2004099168-A2 SUBSTITUTED CARBOXYLIC ACIDS THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266788-A1 Substituted carboxylic acids PTP4A1, PTPRS, G6PC1 LMNA 4745/4885MAPK1 342/4885RAB9A 1691/4885
US-20060094747-A1 Substituted carboxylic acids PTPRS, PTPRO, PTPRJ LMNA 4759/4885MAPK1 430/4885RAB9A 1518/4885
US-20090082392-A1 Substituted Carboxylic Acids PTPRJ, PTPRS, PTPRG LMNA 4712/4885MAPK1 522/4885RAB9A 1656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.